Navigation Links
Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2010 Results Conference Call on Friday, February 25, 2011
Date:2/17/2011

EAST BRUNSWICK, N.J., Feb. 17, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) announced today that its fourth quarter and year-end 2010 financial results will be released on Friday, February 25, 2011, at 7:00 a.m. Eastern Time. Following the announcement, John H. Johnson, Chief Executive Officer, and David Gionco, Group Vice President and Chief Financial Officer, will host an investment community conference call and webcast at 9:00 a.m. Eastern Time to review the Company's financial results and recent business developments.

To participate by telephone, please dial 888-357-3694 (Domestic) or 973-890-8276 (International). The conference identification number is 45733606. The live and archived webcast can be accessed on the investor relations section of the Savient website at www.savient.com. Please log on to Savient's website 15 minutes prior to the start of the call to ensure adequate time for any downloads that may be necessary.

A telephone replay will be available from 12:00 p.m. Eastern Time on Friday, February 25, 2011, through 11:59 p.m. Eastern Time on March 11, 2011 by dialing 800-642-1687 (Domestic) or 706-645-9291 (International) and entering conference ID number 45733606.

ABOUT SAVIENT PHARMACEUTICALS, INC.

Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA™ (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP").  Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA.  Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S.

SVNT - I


'/>"/>
SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Closes Sale of $230 Million in Convertible Senior Notes
2. Savient Announces Proposed Offering of $125 Million in Convertible Senior Notes
3. Savient Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
4. Savient Pharmaceuticals Names John H. Johnson Chief Executive Officer
5. Savient Pharmaceuticals Announces Search for CEO
6. Savient Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
7. Savient Pharmaceuticals Announces Expected Availability of KRYSTEXXA™ for Prescription and Reports Third Quarter 2010 Financial Results
8. Savient Pharmaceuticals to Hold Third Quarter 2010 Financial Results Conference Call on Friday, November 5, 2010
9. Savient Pharmaceuticals to Hold Conference Call on October 26, 2010 at 8:30 a.m. Eastern Time
10. Savient Pharmaceuticals Provides Update on Strategic Alternatives Process
11. Savient Pharmaceuticals Announces Dismissal of Class Action Lawsuit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2017)... -- Endo International plc (NASDAQ: ENDP ) ... Joseph R. Goodwin , U.S. District Court Judge for ... , entered a case management order in MDL 2325, ... Litigation (the "MDL") that includes a provision requiring plaintiffs ... on specific causation within one hundred twenty (120) days ...
(Date:6/3/2017)... 2017  Eli Lilly and Company (NYSE: ... the Phase 3 MONARCH 2 study showed that ... in combination with fulvestrant, significantly improved progression-free survival ... women with hormone-receptor-positive (HR+), human epidermal growth factor ... relapsed or progressed after endocrine therapy (median PFS, ...
(Date:5/30/2017)... AVIV, Israel , May 30, 2017 ... stage pharmaceutical Company specializing in the development of ... will present a company overview at three upcoming ... The 7th Annual LD Micro Invitational: ... Date:                     ...
Breaking Medicine Technology:
(Date:6/23/2017)... ... June 23, 2017 , ... Radabaugh & Associates, a locally ... business owners in North Central West Virginia, is embarking on a cooperative charity ... residents in the region. , The Stepping Stones organization offers a series of ...
(Date:6/22/2017)... ... 2017 , ... Plastic Surgery Associates is proud to report that founding surgeon, ... research and information firm, Castle Connolly, releases their list of the most notable and ... 3rd time that Dr. Canales has been recognized by Castle Connolly. , ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... from the American Heart Association (AHA) to launch a Rheumatic Heart Disease Center, ... prevention and diagnosis of rheumatic heart disease (RHD) in high-risk, financially disadvantaged countries ...
(Date:6/22/2017)... , ... June 22, 2017 , ... ... announced today that it has received certification for ANSI/ASIS PSC.1-2012. The company’s work ... in environments where the rule of law has been degraded. The PSC.1 standard ...
(Date:6/20/2017)... ... June 20, 2017 , ... TwelveStone Health Partners, ... a Nashville-based private equity firm, has invested $3.35 million in the company. ... and Claritas Capital offers the smart money, speed to market and accountability we ...
Breaking Medicine News(10 mins):